prodchem
Aug 25, 2026
India’s position in the global pharmaceutical supply chain makes its exposure to a 100% API tariff commercially significant. The country is the world’s largest producer of generic medicines by volume and remains a major source of active pharmaceutical ingredients for pharmaceutical manufacturers worldwide.
The critical issue for sourcing teams is that the tariff framework does not affect every Indian pharmaceutical business in the same way. Indian generic drug manufacturers are exempted, while Indian API suppliers serving U.S. patented drug supply chains remain exposed unless individual companies secure U.S. agreements.
That distinction can materially change landed costs, supplier competitiveness and purchasing decisions. Procurement teams that treat India’s pharmaceutical sector as one homogeneous supply base could misjudge their actual tariff exposure.
For global buyers, the next step is to map where an API enters the supply chain, who imports it into the U.S. and which final drug category it supports.
India has built a powerful pharmaceutical manufacturing ecosystem covering finished generic medicines, APIs, intermediates and contract manufacturing. Its large production base gives international buyers access to established manufacturing capabilities and competitive supply across a broad range of pharmaceutical ingredients.
The country also plays an important role in the U.S. pharmaceutical market. Indian manufacturers supply generic medicines directly while API producers support both generic and branded drug manufacturing networks.
This creates two distinct trade flows.
The first involves an Indian company exporting a finished generic medicine into the U.S. market. Under the supplied tariff framework, Indian generic manufacturers themselves remain exempt.
The second involves an Indian API producer exporting an ingredient that eventually enters a patented or branded medicine supply chain. That API shipment remains exposed to the full default 100% tariff unless the individual supplier secures an applicable U.S. agreement.
For procurement teams, the difference is fundamental.
The distinction between finished pharmaceuticals and APIs can easily become blurred during sourcing reviews. A company may manufacture both finished generic products and APIs, but the tariff treatment depends on the relevant supply chain and applicable agreement.
A generic manufacturer can therefore remain exempt while an API division or separate API supplier serving a patented-drug chain faces tariff exposure.
This creates a need for entity-level and product-level tariff mapping.
Procurement teams should identify:
The legal entity exporting the product.
The physical manufacturing location.
Whether the shipment contains an API, intermediate or finished pharmaceutical.
The U.S. importer of record.
The final drug supply chain receiving the API.
Whether the supplier has secured a specific U.S. agreement.
Without this information, a buyer may incorrectly assume that an Indian supplier is protected simply because India has a large exempt generic pharmaceutical sector.
For API buyers, the impact of a 100% tariff can be substantial because the tariff applies on top of the existing import economics.
Consider an API shipment with a customs value of $100,000. A 100% tariff would add another $100,000 before other applicable logistics, customs and handling costs are considered.
That can completely change the supplier ranking.
An Indian manufacturer that previously offered the most competitive price may become more expensive than an alternative supplier from another origin. Conversely, a supplier with higher production costs may become attractive if its shipments avoid the full tariff.
Procurement teams should therefore compare landed cost rather than quoted price.
A robust comparison should include:
API purchase price.
Freight and insurance.
Applicable tariff.
Customs and brokerage costs.
Financing and inventory costs.
Quality testing.
Qualification expenses.
Expected lead time.
This calculation should apply to each strategically important API rather than to India as a whole.
The distinction becomes particularly important for APIs entering branded or patented medicines.
A pharmaceutical company may not purchase an API directly from India. It could source through a contract manufacturer, a third-party API distributor or another manufacturing partner.
The Indian API supplier can still sit upstream in the U.S. drug supply chain.
That means procurement teams need visibility beyond their immediate supplier. A buyer that evaluates only its direct vendor may miss tariff exposure further upstream.
This is especially relevant for multinational pharmaceutical companies with complex manufacturing networks. An API can cross several commercial relationships before reaching the facility that produces the finished drug.
Supply-chain visibility is therefore becoming a tariff-management tool.
The tariff framework could create different commercial conditions for India's finished-generic and API businesses.
The exempt generic segment may retain an important competitive advantage in the U.S. market. Indian manufacturers can continue supplying finished generic medicines without the same tariff burden described for exposed API imports.
The API segment serving patented drug supply chains faces a different challenge. Unless individual companies secure U.S. agreements, the full 100% default tariff can raise landed costs and encourage customers to reconsider sourcing arrangements.
This divergence could influence investment decisions inside Indian pharmaceutical companies.
Manufacturers may place greater emphasis on API production intended for domestic or non-U.S. markets, while companies with significant U.S. API exposure may explore local manufacturing, partnerships or other tariff-reducing arrangements.
The first practical step for buyers is to build a detailed exposure map.
A country-level analysis is not sufficient because different Indian suppliers can face different outcomes. Procurement teams should map exposure at the supplier, product and end-use level.
A useful internal review can classify APIs into four groups:
Indian APIs supporting U.S. generic medicines: Confirm the applicable exemption and documentation.
Indian APIs supporting U.S. patented or branded medicines: Assess full 100% tariff exposure unless the supplier has an applicable agreement.
Non-Indian alternative sources: Calculate comparative landed costs and qualification requirements.
Strategic APIs with limited alternatives: Prioritize these for immediate contingency planning.
This segmentation can turn a broad tariff concern into a manageable procurement exercise.
India's API manufacturing strength remains commercially valuable, but tariff exposure can increase the value of alternative production origins.
For critical APIs, procurement teams should consider whether a second qualified source can reduce both tariff risk and supply interruption risk.
Diversification does not necessarily mean replacing Indian suppliers. Instead, it can create a dual-source structure in which buyers retain access to India's manufacturing capabilities while maintaining an alternative route for products with significant U.S. tariff exposure.
Potential strategies include:
Qualifying a second international API manufacturer.
Establishing a domestic U.S. or regional manufacturing relationship.
Using contract manufacturing where economically justified.
Increasing strategic inventory for APIs with long qualification timelines.
Negotiating tariff-sharing arrangements with suppliers.
Reviewing product portfolios for APIs with commercially viable substitutes.
The right strategy will depend on the API's criticality, annual volume and number of qualified manufacturers.
The new tariff environment could also influence how Indian API producers approach the U.S. market.
Suppliers with substantial exposure to patented drug supply chains may have incentives to pursue specific U.S. agreements or explore manufacturing arrangements closer to the end market.
For some companies, the cost of establishing additional production capacity may be justified by the value of maintaining U.S. customers. Others may focus on markets where their existing manufacturing economics remain more competitive.
The outcome could create a more differentiated Indian API market.
Companies with strong regulatory capabilities, reliable quality systems and established U.S. relationships may be better positioned to preserve market access. Smaller suppliers with limited financial flexibility could face greater pressure.
Contract manufacturing can make tariff analysis more difficult because the company buying the API may not control every upstream production decision.
A U.S. pharmaceutical company might work with a contract manufacturer that sources APIs from India. The contract manufacturer could then incorporate the API into a finished drug before the product reaches the U.S. market.
This creates a chain of commercial relationships where tariff exposure needs to be traced to the relevant import transaction.
Procurement teams should therefore ask suppliers for more than a standard country-of-origin declaration. They may also need information about manufacturing location, ownership, import arrangements and the final use of the API.
The more complex the supply chain, the more valuable detailed documentation becomes.
The immediate priority should be exposure identification rather than broad supplier replacement.
Procurement teams can begin with a focused review of high-value and high-criticality APIs:
Identify all Indian-origin API purchases entering U.S.-linked supply chains.
Separate APIs supporting generic medicines from those entering patented drug supply chains.
Confirm the status of each supplier under the applicable U.S. agreement framework.
Model landed cost under the 100% tariff scenario.
Identify qualified alternative suppliers and their capacity.
Review inventory coverage for APIs that cannot be replaced quickly.
Start qualification work for high-risk alternatives.
This process can reveal where the tariff creates a genuine commercial problem and where existing exemptions provide sufficient protection.
The reduced 20% tariff available to companies with an approved onshoring plan through April 2030 provides an important planning horizon for affected businesses.
Indian API suppliers and their U.S. customers can use this period to evaluate domestic production, contract manufacturing, technology transfer and other supply-chain strategies.
The window is long enough to support meaningful manufacturing decisions but short enough that companies cannot afford to postpone qualification work indefinitely.
For high-volume APIs, a four-year period can support capital planning and capacity development. For lower-volume specialty APIs, it may be more practical to maintain qualified international suppliers while managing the tariff through pricing or alternative sourcing.
The optimal approach will vary by product.
India is unlikely to lose its importance in pharmaceutical supply simply because a portion of its API exports faces higher U.S. tariff exposure. Its manufacturing depth, technical expertise and established pharmaceutical infrastructure remain major advantages.
The more immediate change is that buyers must distinguish between different parts of India's pharmaceutical ecosystem.
The exemption for Indian generic manufacturers and the exposure of Indian API suppliers serving U.S. patented drug supply chains create two very different procurement environments. Understanding that distinction can help buyers avoid both unnecessary supplier changes and unexpected tariff costs.
For global sourcing teams, the strategic priority is clear: map API flows to their ultimate use, identify supplier-specific tariff exposure and maintain credible alternatives for the most critical products.
The U.S. tariff framework could therefore accelerate a broader transformation in API sourcing, with buyers placing greater value on supply-chain visibility, geographic diversification and manufacturing flexibility.
Featured Product
Found this useful?
Continue Reading
Analysts note that a large proportion of low carbon hydrogen projects that have actually reached construction are in China
The IEA's Global Hydrogen Review 2026 found that of 5.5 million tonnes per year of CCS hydrogen projects in advanced planning
Saudi Arabia's NEOM Green Hydrogen Project is more than 90% complete and expected to start commercial production in 2027
